Literature DB >> 25736066

Clinical, biochemical, and genetic features of non-classical 21-hydroxylase deficiency in Japanese children.

Kenichi Kashimada1, Tomohiro Ishii, Keisuke Nagasaki, Makoto Ono, Toshihiro Tajima, Ichiro Yokota, Yukihiro Hasegawa.   

Abstract

Non-classical 21-hydroxylase deficiency (NC21-OHD) is a mild form of 21-hydroxylase deficiency lacking apparent symptoms of androgen excess at birth. Most NC21-OHD cases are diagnosed after the onset of puberty, while a substantial number of patients are not diagnosed during childhood. Previous studies have reported ethnic differences in the prevalence of NC21-OHD. To date, the clinical features of NC21-OHD in Japanese children have not been systemically reported. Thus, we performed 3 independent analyses: retrospective analyses of newborn screening in 2 major Japanese cities (Sapporo and Niigata) and a national surveillance collecting clinical information from pediatric endocrinologists throughout the country. During the last 10 years, one case of NC21-OHD was diagnosed by newborn screening in each city, resulting in incidences of 2.0 (95% confidence interval = 0.0-5.9) and 2.1 (0.0-6.2) per 1,000,000 in Sapporo and Niigata, respectively. We collected information from 85% of the 135 Councilors of Japanese Society of Pediatric Endocrinology. Fifteen NC21-OHD patients were diagnosed during childhood, resulting in the estimated prevalence of 0.58 (0.28-1.1) per 1,000,000. Eleven patients were discovered by newborn screening, 7 patients developed hyperandrogenism symptoms (2-8 years of age, median 7), and 9 patients were treated with hydrocortisone at the time of the survey. Ten out of 13 patients showed compound heterozygosity for the P30L mutation of CYP21A2. Our study suggests that the prevalence/incidence of NC21-OHD is lower than that in Western countries, and that the age for initial onset of androgen excess symptoms varies during the prepubertal period.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25736066     DOI: 10.1507/endocrj.EJ14-0377

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  6 in total

1.  Clinical guidelines for the diagnosis and treatment of 21-hydroxylase deficiency (2021 revision).

Authors:  Tomohiro Ishii; Kenichi Kashimada; Naoko Amano; Kei Takasawa; Akari Nakamura-Utsunomiya; Shuichi Yatsuga; Tokuo Mukai; Shinobu Ida; Mitsuhisa Isobe; Masaru Fukushi; Hiroyuki Satoh; Kaoru Yoshino; Michio Otsuki; Takuyuki Katabami; Toshihiro Tajima
Journal:  Clin Pediatr Endocrinol       Date:  2022-04-10

Review 2.  Clinical outcomes and characteristics of P30L mutations in congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Mirjana Kocova; Violeta Anastasovska; Henrik Falhammar
Journal:  Endocrine       Date:  2020-05-05       Impact factor: 3.633

3.  Late onset adrenal insufficiency after adrenalectomy due to latent nonclassical 21-hydroxylase deficiency: A case report.

Authors:  Hiroyuki Hirai; Keisuke Kuwana; Yoshiro Kusano
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.889

4.  Guidelines for diagnosis and treatment of 21-hydroxylase deficiency (2014 revision).

Authors:  Tomohiro Ishii; Makoto Anzo; Masanori Adachi; Kazumichi Onigata; Satoshi Kusuda; Keisuke Nagasaki; Shohei Harada; Reiko Horikawa; Masanori Minagawa; Kanshi Minamitani; Haruo Mizuno; Yuji Yamakami; Masaru Fukushi; Toshihiro Tajima
Journal:  Clin Pediatr Endocrinol       Date:  2015-07-18

5.  Classic and non-classic 21-hydroxylase deficiency can be discriminated from P450 oxidoreductase deficiency in Japanese infants by urinary steroid metabolites.

Authors:  Yuhei Koyama; Keiko Homma; Maki Fukami; Masayuki Miwa; Kazushige Ikeda; Tsutomu Ogata; Mitsuru Murata; Tomonobu Hasegawa
Journal:  Clin Pediatr Endocrinol       Date:  2016-04-28

6.  Newborn screening for congenital adrenal hyperplasia in Tokyo, Japan from 1989 to 2013: a retrospective population-based study.

Authors:  Atsumi Tsuji; Kaoru Konishi; Satomi Hasegawa; Akira Anazawa; Toshikazu Onishi; Makoto Ono; Tomohiro Morio; Teruo Kitagawa; Kenichi Kashimada
Journal:  BMC Pediatr       Date:  2015-12-15       Impact factor: 2.125

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.